UB Paderborn / Katalog / Suche / in CDI

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood, 2018-05, Vol.131 (21), p.2357-2366

2018

Link zum Volltext

Verfügbarkeit prüfen

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Clinical cancer research, 2016-04, Vol.22 (7), p.1572-1582

2016

Link zum Volltext

Verfügbarkeit prüfen

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy

Leukemia & lymphoma, 2019-01, Vol.60 (2), p.519-522

2019

Link zum Volltext

Verfügbarkeit prüfen

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1

Leukemia & lymphoma, 2011-09, Vol.52 (9), p.1758-1769

2011

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

The New England journal of medicine, 2020-07, Vol.383 (5), p.498-500

2020

Link zum Volltext

Verfügbarkeit prüfen

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

Haematologica (Roma), 2010-02, Vol.95 (2), p.329-332

2010

Link zum Volltext

Verfügbarkeit prüfen

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica (Roma), 2013-08, Vol.98 (8), p.1259-1263

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Blood, 2021-01, Vol.137 (2), p.185-189

2021

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

Journal of clinical oncology, 2021-02, Vol.39 (6), p.576-585

2021

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

British journal of haematology, 2022-02, Vol.196 (4), p.947-953

2022

Link zum Volltext

Verfügbarkeit prüfen

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Leukemia, 2017-06, Vol.31 (6), p.1340-1347

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clinical cancer research, 2021-08, Vol.27 (16), p.4531-4538

2021

Link zum Volltext

Verfügbarkeit prüfen

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2015-12, Vol.100 (12), p.1571-1578

2015

Link zum Volltext

Verfügbarkeit prüfen

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Blood, 2021-11, Vol.138 (19), p.1843-1854

2021

Link zum Volltext

Verfügbarkeit prüfen

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Leukemia, 2013-12, Vol.27 (12), p.2311-2321

2013

Link zum Volltext

Verfügbarkeit prüfen

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

British journal of haematology, 2020-06, Vol.189 (6), p.1165-1170

2020

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

Leukemia, 2017-02, Vol.31 (2), p.340-349

2017

Link zum Volltext

Verfügbarkeit prüfen

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

JAMA oncology, 2016-12, Vol.2 (12), p.1656

2016

Link zum Volltext

Verfügbarkeit prüfen

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2016-06, Vol.101 (6), p.e254-e258

2016

Link zum Volltext

Verfügbarkeit prüfen

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

JAMA dermatology (Chicago, Ill.), 2016-06, Vol.152 (6), p.698

2016

Link zum Volltext

Verfügbarkeit prüfen

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

Clinical cancer research, 2004-02, Vol.10 (3), p.1047-1056

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Leukemia, 2013-09, Vol.27 (9), p.1920-1923

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Aktive Filter

Suchergebnisse filtern